Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
CyPath® Lung’s test result of “Unlikely Lung Cancer” directly prevented a robotic bronchoscopic biopsy or high-risk percutaneous biopsy in response to imaging that showed several new, small non-calcified pulmonary nodules for a high-risk 85-year-old patient with a greater than 20-pack-year smoking history, COPD and asbestos exposure. Based on the CyPath® Lung test result, the patient, who initially expressed a strong desire for more invasive procedures, agreed to “watchful waiting.” In the intervening three months, all non-calcified nodules have resolved.
The case study was presented by Gordon H. Downie, MD, PhD, Director of the Pulmonary Nodule Clinic at
“The case study highlights how CyPath® Lung can reduce anxiety and unnecessary and risky invasive medical procedures, while at the same time increasing diagnostic accuracy,” bioAffinity Technologies’ President and Chief Executive Officer Maria Zannes said. “The case study also illustrates why and how CyPath® Lung can lower healthcare costs to both the patient and America’s healthcare system, as detailed in the peer-reviewed study on the economic impact of CyPath® Lung published in the Journal of Health Economics Outcomes and Research.”
The study, authored by pulmonologists Michael Morris, MD, and Sheila Habib, MD, found that an average cost savings of
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding CyPath® Lung reducing anxiety and unnecessary and risky invasive medical procedures; increasing diagnostic accuracy; and CyPath® Lung lowering healthcare costs to both the patient and America’s healthcare system for an average cost savings of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313929796/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.